{"title":"[乙型肝炎功能性治愈的 HBsAg 轨迹和关键阈值]。","authors":"X E Liang, Z H Liu, Y Y Li, R Fan, J L Hou","doi":"10.3760/cma.j.cn501113-20240902-00466","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic hepatitis B virus (HBV) infection remains a pivotal global public health concern. Attaining a functional cure for hepatitis B continues to be a hot and difficult issue that requires immediate attention in clinical practice. There are currently nucleos(t)ide analogues (NAs) that can persistently suppress HBV DNA; however, the functional cure rate of pegylated interferon alfa (PEG-IFN-α) alone or in combination with NAs has not yet met clinical needs. The research and development on novel mechanisms for HBV antiviral drugs, especially small nucleic acid drugs, has brought breakthroughs to the functional cure of hepatitis B. The functional cure trajectory mapping and its prediction model can guide the selection of clinical treatment strategies based on the longitudinal data for HBsAg at various time intervals. The personalized management of hepatitis B patients can be optimized by utilizing varying HBsAg levels as a key watershed to aid in the screening of subjects in clinical trials.</p>","PeriodicalId":24006,"journal":{"name":"中华肝脏病杂志","volume":"32 ","pages":"961-964"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[HBsAg trajectory and key watersheds towards functional cure of hepatitis B].\",\"authors\":\"X E Liang, Z H Liu, Y Y Li, R Fan, J L Hou\",\"doi\":\"10.3760/cma.j.cn501113-20240902-00466\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Chronic hepatitis B virus (HBV) infection remains a pivotal global public health concern. Attaining a functional cure for hepatitis B continues to be a hot and difficult issue that requires immediate attention in clinical practice. There are currently nucleos(t)ide analogues (NAs) that can persistently suppress HBV DNA; however, the functional cure rate of pegylated interferon alfa (PEG-IFN-α) alone or in combination with NAs has not yet met clinical needs. The research and development on novel mechanisms for HBV antiviral drugs, especially small nucleic acid drugs, has brought breakthroughs to the functional cure of hepatitis B. The functional cure trajectory mapping and its prediction model can guide the selection of clinical treatment strategies based on the longitudinal data for HBsAg at various time intervals. The personalized management of hepatitis B patients can be optimized by utilizing varying HBsAg levels as a key watershed to aid in the screening of subjects in clinical trials.</p>\",\"PeriodicalId\":24006,\"journal\":{\"name\":\"中华肝脏病杂志\",\"volume\":\"32 \",\"pages\":\"961-964\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华肝脏病杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn501113-20240902-00466\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华肝脏病杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn501113-20240902-00466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
慢性乙型肝炎病毒(HBV)感染仍然是全球健康面临的一个重要挑战。由于目前的核苷(t)ide 类似物(NAs)药物库主要实现了对 HBV DNA 的持续抑制,但却无法完全满足临床需求,因此在临床环境中,追求乙型肝炎的功能性治愈仍然是一个艰巨而复杂的问题。单独使用聚乙二醇干扰素(PEG-IFN)或将其与 NAs 联用,仍无法满足功能性治愈的迫切临床需求。然而,通过研究和开发具有新机制的抗病毒药物,特别是小核酸药物,乙肝治疗取得了突破性进展,开创了功能性治愈前景的新纪元。利用跨越多个时间点的 HBsAg 水平纵向数据,我们现在可以勾勒出实现 HBV 功能性治愈的轨迹,并设计出完善临床治疗方案的预测模型。HBsAg 水平的两个关键阈值成为重要的里程碑,有助于为临床试验选择合格的参与者。筛查工作的改进加强了对乙型肝炎的个性化管理,使干预措施符合患者的个体需求,并最大限度地提高疗效。
[HBsAg trajectory and key watersheds towards functional cure of hepatitis B].
Chronic hepatitis B virus (HBV) infection remains a pivotal global public health concern. Attaining a functional cure for hepatitis B continues to be a hot and difficult issue that requires immediate attention in clinical practice. There are currently nucleos(t)ide analogues (NAs) that can persistently suppress HBV DNA; however, the functional cure rate of pegylated interferon alfa (PEG-IFN-α) alone or in combination with NAs has not yet met clinical needs. The research and development on novel mechanisms for HBV antiviral drugs, especially small nucleic acid drugs, has brought breakthroughs to the functional cure of hepatitis B. The functional cure trajectory mapping and its prediction model can guide the selection of clinical treatment strategies based on the longitudinal data for HBsAg at various time intervals. The personalized management of hepatitis B patients can be optimized by utilizing varying HBsAg levels as a key watershed to aid in the screening of subjects in clinical trials.